Novartis said the annualized cost of Zolgensma will be $425,000 a year for five years. "Novartis' Zolgensma Approved for Sale in U.S. to Treat SMA in Infants at $425,000 a Year," at 1308 ET, misstakenly called the company Novaratis in the last paragraph.

(END) Dow Jones Newswires

May 24, 2019 18:36 ET (22:36 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Novartis Charts.
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Novartis Charts.